angiopeptin

Angiopeptin, a cyclic octapeptide analogue of somatostatin, markedly inhibits myointimal proliferation in response to endothelial cell injury. Angiopeptin is a potent and full agonists to inhibit adenylate cyclase or stimulate extracellular acidification through the sst2 or sst5 receptor. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 production[1][2].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> GPCR/G Protein >> Somatostatin Receptor

Angiopeptin (20 and 50μg/kg; i.h.) significantly inhibits neointimal formation[1]. Angiopeptin (20 μg/kg; per day) significantly inhibits coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%[1]. Animal Model: Rat (model of myointimal proliferation)[1] Dosage: 20 and 50 μg/kg Administration: I.h. Result: Inhibited neointimal formation. Animal Model: New Zealand white rabbit (model of myointimal proliferation)[1] Dosage: 20 μg/kg Administration: Per day Result: Inhibited coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%.

[1]. Lundergan CF, et al. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol. 1991;17(6 Suppl B):132B-136B.

[2]. Alderton F, et al. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol. 2001;132(3):760-766.